These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 17920256)
21. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642 [TBL] [Abstract][Full Text] [Related]
22. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Tashkin DP; Donohue JF; Mahler DA; Huang H; Goodwin E; Schaefer K; Hanrahan JP; Andrews WT Respir Med; 2009 Apr; 103(4):516-24. PubMed ID: 19208459 [TBL] [Abstract][Full Text] [Related]
23. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Maesen FP; Smeets JJ; Sledsens TJ; Wald FD; Cornelissen PJ Eur Respir J; 1995 Sep; 8(9):1506-13. PubMed ID: 8575576 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial. Tashkin DP; Celli BR; Decramer M; Lystig T; Liu D; Kesten S COPD; 2012 Jun; 9(3):289-96. PubMed ID: 22432932 [TBL] [Abstract][Full Text] [Related]
25. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. van Noord JA; Aumann JL; Janssens E; Smeets JJ; Verhaert J; Disse B; Mueller A; Cornelissen PJ Eur Respir J; 2005 Aug; 26(2):214-22. PubMed ID: 16055868 [TBL] [Abstract][Full Text] [Related]
26. Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients. Ichinose M; Fujimoto T; Fukuchi Y Respir Med; 2010 Feb; 104(2):228-36. PubMed ID: 19969446 [TBL] [Abstract][Full Text] [Related]
27. Bronchodilator responsiveness in patients with COPD. Tashkin DP; Celli B; Decramer M; Liu D; Burkhart D; Cassino C; Kesten S Eur Respir J; 2008 Apr; 31(4):742-50. PubMed ID: 18256071 [TBL] [Abstract][Full Text] [Related]
29. Paradoxical trough effects of triple therapy with budesonide/formoterol and tiotropium bromide on pulmonary function outcomes in COPD. Williamson PA; Short PM; Clearie KL; Vaidyanathan S; Fardon TC; Howaniec LJ; Lipworth BJ Chest; 2010 Sep; 138(3):595-604. PubMed ID: 20418370 [TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD. Abrahams R; Moroni-Zentgraf P; Ramsdell J; Schmidt H; Joseph E; Karpel J Respir Med; 2013 Jun; 107(6):854-62. PubMed ID: 23490224 [TBL] [Abstract][Full Text] [Related]
31. Double-blind randomized parallel group study comparing the efficacy and safety of tiotropium and ipratropium in the treatment of COPD patients in Taiwan. Hsu JY; Perng RP; Lu JY; Wu CP; Huang MS; Luh KT; Yang PC J Formos Med Assoc; 2006 Sep; 105(9):708-14. PubMed ID: 16959618 [TBL] [Abstract][Full Text] [Related]
32. Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease. Covelli H; Bhattacharya S; Cassino C; Conoscenti C; Kesten S Pharmacotherapy; 2005 Dec; 25(12):1708-18. PubMed ID: 16305289 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial. Fukuchi Y; Fernandez L; Kuo HP; Mahayiddin A; Celli B; Decramer M; Kesten S; Liu D; Tashkin D Respirology; 2011 Jul; 16(5):825-35. PubMed ID: 21539680 [TBL] [Abstract][Full Text] [Related]
36. Therapeutic conversion of the combination of ipratropium and albuterol to tiotropium in patients with chronic obstructive pulmonary disease. Niewoehner DE; Lapidus R; Cote C; Sharafkhaneh A; Plautz M; Johnson P; Kesten S Pulm Pharmacol Ther; 2009 Dec; 22(6):587-92. PubMed ID: 19737620 [TBL] [Abstract][Full Text] [Related]
37. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial. Bölükbas S; Eberlein M; Eckhoff J; Schirren J Eur J Cardiothorac Surg; 2011 Jun; 39(6):995-1000. PubMed ID: 20970351 [TBL] [Abstract][Full Text] [Related]
38. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Hanania NA; Crater GD; Morris AN; Emmett AH; O'Dell DM; Niewoehner DE Respir Med; 2012 Jan; 106(1):91-101. PubMed ID: 22040533 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease. Tang Y; Massey D; Zhong NS Chin Med J (Engl); 2013; 126(19):3603-7. PubMed ID: 24112149 [TBL] [Abstract][Full Text] [Related]
40. [Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities]. Beeh KM; Beier J; Buhl R; Stark-Lorenzen P; Gerken F; Metzdorf N; Pneumologie; 2006 Jun; 60(6):341-6. PubMed ID: 16761228 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]